In conclusion, our study suggested that ropivacaine inhibited the expression of HIF-1α in H1299 and A549 lung cancer cells, hence reducing the expression of its downstream effectors VEGF and MMPs and decreasing the ability of lung cancer invasion and metastasis potential per se. Here, HIF1A is linked to lung carcinoma.